Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. - Wikidata - awgldk - TriplyDB

Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.

Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.

http://www.wikidata.org/entity/Q37158481

about

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer.The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.Immunotherapeutic Approaches to Biliary Cancer.Co-stimulate or Co-inhibit Regulatory T Cells, Which Side to Go?Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cells.The immune molecular landscape of the B7 and TNFR immunoregulatory ligand-receptor families in head and neck cancer: A comprehensive overview and the immunotherapeutic implications.The comprehensive molecular landscape of the immunologic co-stimulator B7 and TNFR ligand receptor families in colorectal cancer: immunotherapeutic implications with microsatellite instability

P2860

Q33650470-3D116CD8-CEC6-4A42-8F87-DC506BD7FA75 Q33873731-2251C560-17A3-4836-BE36-9A73BF4CD9DB Q37224577-7942B1D4-D2A0-4084-9EA4-E8E6E21B3E79 Q38666253-F4748F5F-9CB3-4062-B805-1C8A77AD348F Q38703148-AEC6FF13-3895-4A12-BA5E-8B872BEF7ECF Q38897638-3488453E-DEBB-45A0-B33A-4F773611B4B4 Q47108014-4879EA8B-A07E-48D6-BAD1-B01B8E88A4CB Q53359622-F947BE18-1C3F-4CBD-8D72-5E8866F8CA5B Q57127709-54BDC769-62B5-4FFD-8FA2-176CE312BAD4

P2860

Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.

http://www.wikidata.org/entity/Q37158481

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.

@en

Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.

@nl

type

label

Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.

@en

Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.

@nl

prefLabel

Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.

@en

Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.

@nl

P1433

Q37158481-5035DD25-4DFB-4382-963A-D014AD5255DD

P1476

Q37158481-0B69FCD2-CD8B-4C47-BD81-7DA4858BC9F2

P2093

Q37158481-56C5C8B7-1341-4F09-BC39-67AA7ACE1611

Q37158481-8B9FACC1-5E8C-40F4-9B25-A6AFC4151D0A

Q37158481-A4077070-3F4A-46D3-811A-72FD895DFF2F

P2860

Q37158481-015D06BF-4D44-4AF1-99C5-36A8928CE5B9

Q37158481-0650B403-68B2-4C07-AD43-4ECB30007C37

Q37158481-0E8136D5-11E6-4F26-B421-A50D8EFD97F2

Q37158481-0F6BB742-67BE-4428-9116-4FD239315D4B

Q37158481-0FBD54B1-EA4C-4D3C-BB0B-3F9116FACF60

Q37158481-10512D96-74EE-414F-827C-EA182F34F4B8

Q37158481-1284FDAC-0F22-4DDD-84E9-726CFFD2713C

Q37158481-12870E0C-AD3D-4527-A3F0-5CFACFC75FB7

Q37158481-1420B389-481A-43D4-8C55-470D2F85BA34

Q37158481-150242DA-79E2-4A9E-A1CE-E09A0C9B67D2

P304

Q37158481-10324960-A100-4808-86F4-99C45F7F82F2

P31

Q37158481-85b296ca-204e-46db-a930-1e3aaae20a11

Q37158481-899AE4F0-C0A9-4DAA-994F-4C07F94A20DA

P356

Q37158481-95A0D4C4-5B23-49BE-BC5B-28A431D14AB1

P433

Q37158481-C9722E84-F34A-4353-8332-11B957F0FE45

P478

Q37158481-D02DEA5D-8761-4CDC-A35E-763EC4DCD6B2

P50

Q37158481-F32EB6D1-CDFD-44BD-97DE-35C2E0B928E1

P577

Q37158481-3E695E1D-25C7-498D-9970-E679FC327864

P698

Q37158481-C8563791-460C-4320-BCBA-86591869C9E5

P921

Q37158481-886B9FC7-C078-4B13-B015-184CBE65ACCE

P932

Q37158481-07526B3B-B376-445C-86B1-235EC53B48B9

P356

P1433

P1476

Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1

@en

P2093

Gopichand Pendurti

http://www.w3.org/2001/XMLSchema#string

Justin Kaner

http://www.w3.org/2001/XMLSchema#string

Xingxing Zang

http://www.w3.org/2001/XMLSchema#string

P2860

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Hallmarks of Cancer: The Next Generation

B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

B7-H5 costimulates human T cells via CD28H

B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival

Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

P304

1169-1186

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT.15.78

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26567614

http://www.w3.org/2001/XMLSchema#string

P921

P932

4976877

http://www.w3.org/2001/XMLSchema#string